Jasper Therapeutics (NASDAQ:JSPR) Now Covered by JMP Securities

JMP Securities assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note published on Monday morning, MarketBeat.com reports. The firm issued an outperform rating and a $70.00 price objective on the stock.

JSPR has been the topic of a number of other research reports. Royal Bank of Canada cut their target price on Jasper Therapeutics from $70.00 to $68.00 and set an outperform rating on the stock in a research note on Wednesday, August 14th. Evercore ISI reaffirmed an outperform rating and set a $65.00 target price on shares of Jasper Therapeutics in a research note on Monday, August 26th. BTIG Research began coverage on Jasper Therapeutics in a research note on Monday, July 8th. They set a buy rating and a $90.00 target price on the stock. HC Wainwright reaffirmed a buy rating and set a $65.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, August 13th. Finally, Stifel Nicolaus began coverage on Jasper Therapeutics in a research note on Thursday, June 27th. They set a buy rating and a $86.00 target price on the stock. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $73.00.

Jasper Therapeutics Price Performance

Shares of JSPR stock opened at $20.66 on Monday. Jasper Therapeutics has a 1 year low of $4.00 and a 1 year high of $31.01. The stock’s 50 day simple moving average is $19.46 and its two-hundred day simple moving average is $22.68. The company has a market cap of $311.15 million, a PE ratio of -3.67 and a beta of 2.22.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. Equities research analysts expect that Jasper Therapeutics will post -4.16 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new position in Jasper Therapeutics in the first quarter worth approximately $306,000. Rhumbline Advisers bought a new stake in Jasper Therapeutics during the 2nd quarter valued at $300,000. American Century Companies Inc. boosted its position in Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after acquiring an additional 3,032 shares in the last quarter. Concurrent Investment Advisors LLC bought a new stake in Jasper Therapeutics during the 1st quarter valued at $599,000. Finally, Bank of New York Mellon Corp bought a new stake in Jasper Therapeutics during the 2nd quarter valued at $740,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.